Altre lingue Core One Labs Inc.

Azioni

COOL

CA21872J3073

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 19:43:46 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,19 ^CAD	+5,56%		-19,15%	-34,48%

29/02	Core One Labs Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 dicembre 2023	CI
2023	Core One Labs Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Core One Labs : Announces Non-Brokered Private Placement	09/04
Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding	09/04
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	29/02
Core One Labs Inc.: Core One Labs Inc. kündigt Erstabkommen zum potenziellen Verkauf seines proprietären biosynthetischen Psilocybins an, das den globalen Markteinstieg erleichtern soll	09/12
Core One Labs Inc.: Core One Labs-Tochter Akome meldet eindrucksvolle Ergebnisse seiner psychedelischen Bio-Wirkstoffverbindungen, die zur Bekämpfung von Alzheimer und Parkinson entwickelt wurden und die das Potenzial zeigen, derzeitige Behandlungsmethoden zu übertreffen	02/12
Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	03/11
Core One Labs Inc. announced that it has received CAD 0.2 million in funding	18/09/23
Core One Labs : Announces Non-Brokered Private Placement	11/09/23
Core One Labs Inc. announced that it expects to receive CAD 1 million in funding	11/09/23
Core One Labs Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	29/08/23
Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions	24/08/23
Core One Labs Inc.: Core Ones Akome meldet bahnbrechende positive Ergebnisse aus seiner zweiten Runde von Tiermodellstudien der Phase 1 zu Bio-Verbindungen, die auf Alzheimer und Parkinson abzielen	05/08/23
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer?s and Parkinson's Disease	05/08/23
Core One Labs : Applauds Groundbreaking Research on Psilocybin as a Potential Anorexia Treatment	04/08/23
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023	03/08/23
Core One Labs Inc.: Core One Labs-Tochter Awakened Biosciences berichtet über bahnbrechenden Fortschritt bei der Isolierung und Reinigung von Psilocybin aus Pilz-Biomasse	02/08/23
Core One Labs Inc.: Core One-Tochter Akome erzielt in der vorläufigen Phase-1-Tiermodellstudie für die Bio-Verbindung, die auf Alzheimer und Parkinson abzielt, positive Ergebnisse	29/07/23
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer?s and Parkinson?s Disease	29/07/23
Core One Labs Inc.: Core One Labs unterzeichnet eine Absichtserklärung für den Erstverkauf seiner psychedelischen Wirkstoffverbindungen	22/07/23
Core One Labs : Applauds California Assembly Health Committee’s Approval of Bill to Legalize Psychedelics	19/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Core One Labs Inc.

Azioni

COOL

CA21872J3073

Altre lingue

Filtri